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Smoking causes not only cancer but also cardio-
vascular diseases such as stroke, coronary heart 
disease, hypertension, thromboembolism, and 
peripheral artery disease, lung disease such as 
chronic obstructive pulmonary disease (COPD), 
and many other diseases, including (but not 
limited to) type 2 diabetes, rheumatoid arthritis, 
cataracts, and macular degeneration.1 These dis-
eases develop with age and contribute in differ-
ent measure to the current epidemic of chronic 
noncommunicable diseases that are associated 
with smoking and aging.1,2
Even though the effects of smoking are broad 
and devastating, much smoking-related research 
traditionally focuses on the lung because the 
lung is considered to be the primary target 
organ of smoking.3 Even though COPD is one 
of the major consequences of smoking, COPD 
usually does not exist by itself, because it is 
almost invariably associated with concomitant 
chronic respiratory and nonrespiratory diseases3,4 
that contribute to the clinical manifestations 
and severity of the smoking-induced systemic 
disease.
COPD, as defined by the Global Initiative for 
Chronic Obstructive Lung Disease, is diagnosed 
as persistent airf low limitation in smokers.3 
This definition has limitations for clinical prac-
tice, because it does not mention symptoms and 
applies only to smokers in whom airflow limita-
tion has developed. In fact, the only COPD we 
know well is the one that is defined as airflow 
limitation in smokers, because most of the data 
available on the pathophysiology and manage-
ment of COPD have been derived from smokers 
with airflow limitation that was defined accord-
ing to spirometric assessment.3
Woodruff and colleagues report in this issue 
of the Journal5 on a group of smokers with nor-
mal findings on spirometry who have chronic 
respiratory symptoms, exacerbations (identified 
as the use of antibiotic agents, systemic gluco-
corticoids, or both or an event of health care 
utilization such as an office visit, hospital ad-
mission, or emergency department visit for a 
respiratory flare-up), lower than normal exercise 
tolerance, and imaging evidence of bronchiolitis. 
Thus, they conclude that spirometry is not ade-
quate to define the breadth of smoking-induced 
lung disease. These results confirm and extend 
the findings of another recent large study that 
showed that more than 50% of symptomatic 
smokers with normal findings on spirometry 
have considerable respiratory-related impairment 
and evidence of emphysema on imaging.6 Most 
of these symptomatic smokers with normal find-
ings on spirometry are often treated (without 
any evidence) with inhaled bronchodilators and 
glucocorticoids — that is, they are treated like 
patients with COPD, but they do not have COPD 
according to our current definition.
These two studies introduce an important 
paradigm shift in our approach to smoking-
induced disease. Both studies show that patients 
who have chronic respiratory symptoms without 
airflow limitation have the same respiratory con-
sequences as those who have mild-to-moderate 
airflow obstruction and get the official diagnos-
tic label of COPD. This finding tells us that 
symptoms are at least as sensitive as airf low 
limitation in establishing a diagnosis of smoking-
induced disease. The observation that bronchi-
olitis and emphysema that are detected by means 
of computed tomographic scanning may be 
present in some smokers without airflow limita-
tion lends a firm biologic basis to these infer-
ences and reminds us, once again, that COPD 
may be a disease of the “lung’s quiet zone,” as 
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defined by Mead almost 50 years ago — a place 
where there can be pathobiologic changes that 
are not detected by changes in the forced expira-
tory volume in 1 second (FEV1).
7 These two stud-
ies have identified a complex clinical syndrome 
that is treated as COPD in practice even when 
airflow limitation is not present — a syndrome 
that very much resembles heart failure without 
impairment of ejection fraction.8
It would be useful if we had a way to detect 
abnormalities before they manifest clinically so 
that intervention can prevent full-blown disease. 
For more than 50 years, smoking-related re-
search has focused on measurements of lung 
function, including spirometry, to detect early 
COPD.9,10 Now we know that symptoms can be at 
least as sensitive, and certainly more useful, in 
identifying patients who need early interven-
tion.5,6,10 This finding clearly suggests that the 
FEV1 is not sensitive in a large majority of smokers 
and may be just one of the tools needed to make 
an early diagnosis in a subgroup of smokers.
Using the COPD Assessment Test (CAT) ques-
tionnaire to investigate symptoms,11 Woodruff 
et al. found that both respiratory symptoms 
(cough and sputum) and more systemic or less 
specific symptoms (dyspnea, wheezing, and lim-
itation of activities and energy) are equally dis-
tributed among symptomatic smokers, regard-
less of whether there is impairment in the FEV1. 
Even though the CAT is meant to be specific for 
COPD,11 most of its domains are rather nonspe-
cific and may reflect concomitant respiratory 
diseases (asthma and bronchiectasis) and non-
respiratory diseases (heart failure, ischemic heart 
disease, obesity, and depression) that contribute 
to the multifaceted chronic diseases induced by 
smoking. Interestingly, chronic bronchitis, which 
was once considered to be one of two character-
istic components of COPD (the other was em-
physema), is present in a minority of smokers, 
which suggests that systemic symptoms, such as 
chest tightness, breathlessness, and limited en-
ergy, may be more representative of the broad 
effects of smoking.
Both studies5,6 appropriately focused on the 
presence of a history of smoking as the main 
entry criterion, but the focus of both studies was 
the lung as the target organ and COPD as the 
primary disease to be investigated. The results 
suggest that smoking itself should be considered 
the disease and should be approached in all its 
complexity.1,12 Since our treatment database was 
derived only from people with airflow obstruc-
tion, we should probably limit recommendations 
to the diagnosis and treatment of the spiromet-
rically confirmed COPD that is defined accord-
ing to current guidelines.3 These new studies5,6 
help us define this new cohort of patients with 
chronic respiratory symptoms without obstruc-
tion. It is now up to us to figure out how to treat 
them in order to help reduce symptoms and 
prevent exacerbations.3,4,12
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